Literature DB >> 21170488

The role of the TGF-β coreceptor endoglin in cancer.

Eduardo Pérez-Gómez1, Gaelle Del Castillo, Santibáñez Juan Francisco, Jose Miguel López-Novoa, Carmelo Bernabéu, Miguel Quintanilla.   

Abstract

Endoglin (CD105) is an auxiliary membrane receptor of transforming growth factor beta (TGF-β) that interacts with type I and type II TGF-β receptors and modulates TGF-β signaling. Endoglin is overexpressed in the tumor-associated vascular endothelium, where it modulates angiogenesis. This feature makes endoglin a promising target for antiangiogenic cancer therapy. In addition, recent studies on human and experimental models of carcinogenesis point to an important tumor cell-autonomous role of endoglin by regulating proliferation, migration, invasion, and metastasis. These studies suggest that endoglin behaves as a suppressor of malignancy in experimental and human epithelial carcinogenesis, although it can also promote metastasis in other types of cancer. In this review, we evaluate the implication of endoglin in tumor development underlying studies developed in our laboratories in recent years.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21170488      PMCID: PMC5763795          DOI: 10.1100/tsw.2010.230

Source DB:  PubMed          Journal:  ScientificWorldJournal        ISSN: 1537-744X


  41 in total

1.  Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Authors:  Adam D Steg; Kerri S Bevis; Ashwini A Katre; Angela Ziebarth; Zachary C Dobbin; Ronald D Alvarez; Kui Zhang; Michael Conner; Charles N Landen
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

Review 2.  PECAM-1 isoforms, eNOS and endoglin axis in regulation of angiogenesis.

Authors:  Sunyoung Park; Christine M Sorenson; Nader Sheibani
Journal:  Clin Sci (Lond)       Date:  2015-08       Impact factor: 6.124

3.  Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Authors:  Angela J Ziebarth; Somaira Nowsheen; Adam D Steg; Monjri M Shah; Ashwini A Katre; Zachary C Dobbin; Hee-Dong Han; Gabriel Lopez-Berestein; Anil K Sood; Michael Conner; Eddy S Yang; Charles N Landen
Journal:  Clin Cancer Res       Date:  2012-11-12       Impact factor: 12.531

4.  Transforming growth factor β in cancer: Janus, the two-faced god.

Authors:  David Salomon
Journal:  J Natl Cancer Inst       Date:  2014-02       Impact factor: 13.506

5.  Elevated CCN2 expression in scleroderma: a putative role for the TGFβ accessory receptors TGFβRIII and endoglin.

Authors:  Alan M Holmes; Markella Ponticos; Xu Shi-Wen; Christopher P Denton; David J Abraham
Journal:  J Cell Commun Signal       Date:  2011-07-19       Impact factor: 5.782

Review 6.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

7.  Improved survival outcomes in cancer patients with hereditary hemorrhagic telangiectasia.

Authors:  Christine W Duarte; Kimberly Murray; F Lee Lucas; Kathleen Fairfield; Heather Miller; Peter Brooks; Calvin P H Vary
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-05       Impact factor: 4.254

8.  Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.

Authors:  M Paauwe; R C Heijkants; C H Oudt; G W van Pelt; C Cui; C P Theuer; J C H Hardwick; C F M Sier; L J A C Hawinkels
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

Review 9.  Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

Authors:  Orit Jacobson; Xiaoyuan Chen
Journal:  Pharmacol Rev       Date:  2013-09-24       Impact factor: 25.468

10.  Src-mediated post-translational regulation of endoglin stability and function is critical for angiogenesis.

Authors:  Christopher C Pan; Sanjay Kumar; Nirav Shah; Dale G Hoyt; Lukas J A C Hawinkels; Karthikeyan Mythreye; Nam Y Lee
Journal:  J Biol Chem       Date:  2014-07-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.